Concepedia

Author

Sylvie Lorenzen

Klinikum rechts der Isar

Also Known As

Begot, Sylvie, Bégot, Sylvie, Carlos Jose Narvaez, D. Horst, Dirk Arnold, L. Sylvie, Lorenzen Sylvie, Lorenzen, Sievert, Lorenzen, Sylvie, S Lorenzen

306

Publications

6.1K

Citations

37

H-Index

42

Concepts

All Affiliations

Klinikum rechts der IsarTechnical University of MunichCharité - Universitätsmedizin BerlinKrankenhaus NordwestUniversity Hospital Frankfurt
SL

About

Sylvie Lorenzen is an author at Klinikum rechts der Isar specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

33

3K

2

Gastroenterology

15

19

2.2K

3

Health Sciences

8

8

1K

4

Biostatistics

1

1

74

5

Clinical Immunology

1

1

51

Sylvie Lorenzen

×

66

Publications

4.6K

Citations

32

H-Index

YearCitations

PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial

Florian Lordick, Katja Ott, Bernd‐Joachim Krause,

The Lancet Oncology

2007

803

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk,

The Lancet Oncology

2016

713

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo,

The Lancet Oncology

2019

276

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI

Salah‐Eddin Al‐Batran, Thorsten Oliver Goetze, Daniel Mueller,

BMC Cancer

2017

218

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial

Sylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss‐Patience,

Journal of Clinical Oncology

2023

173

Comparison of Integrin α<sub>v</sub>β<sub>3</sub> Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using <sup>18</sup>F-Galacto-RGD and <sup>18</sup>F-FDG

Ambros J. Beer, Sylvie Lorenzen, Stephan Metz,

Journal of Nuclear Medicine

2007

164

Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial

Sylvie Lorenzen, Marcus Hentrich, C. Haberl,

Annals of Oncology

2007

132

EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma

Stefano Ferrari, Stefan Bielack, Sigbjørn Smeland,

Tumori Journal

2017

119

Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy

Sylvie Lorenzen, Peter Thuss‐Patience, Salah‐Eddin Al‐Batran,

Annals of Oncology

2013

117

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Markus Moehler, Annett Maderer, Peter Thuss‐Patience,

Annals of Oncology

2020

110

Page 1